Cited by 65Medical Imaging Techniques and ApplicationsLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non–Small Cell Lung Cancer Patients

Open access
Kramer, Gerbrand Maria, Frings, Virginie, Hoetjes, Nikie, Hoekstra, Otto S., Smit, Egbert F., de Langen, Adrianus Johannes, Boellaard, Ronald·2016·Journal of Nuclear Medicine

Abstract

UNLABELLED: Change in (18)F-FDG uptake may predict response to anticancer treatment. The PERCIST suggest a threshold of 30% change in SUV to define partial response and progressive disease. Evidence underlying these thresholds consists of mixed stand-alone PET and PET/CT data with variable uptake intervals and no consensus on the number of lesions to be assessed. Additionally, there is increasing interest in alternative (18)F-FDG uptake measures such as metabolically active tumor volume and total lesion glycolysis (TLG). The aim of this study was to comprehensively investigate the repeatability of various quantitative whole-body (18)F-FDG metrics in non-small cell lung cancer (NSCLC) patients as a function of tracer uptake interval and lesion selection strategies. METHODS: Eleven NSCLC patients, with at least 1 intrathoracic lesion 3 cm or greater, underwent double baseline whole-body (18)F-FDG PET/CT scans at 60 and 90 min after injection within 3 d. All (18)F-FDG-avid tumors were delineated with an 50% threshold of SUVpeak adapted for local background. SUVmax, SUVmean, SUVpeak, TLG, metabolically active tumor volume, and tumor-to-blood and -liver ratios were evaluated, as well as the influence of lesion selection and 2 methods for correction of uptake time differences. RESULTS: The best repeatability was found using the SUV metrics of the averaged PERCIST target lesions (repeatability coefficients < 10%). The correlation between test and retest scans was strong for all uptake measures at either uptake interval (intraclass correlation coefficient > 0.97 and R(2) > 0.98). There were no significant differences in repeatability between data obtained 60 and 90 min after injection. When only PERCIST-defined target lesions were included (n = 34), repeatability improved for all uptake values. Normalization to liver or blood uptake or glucose correction did not improve repeatability. However, after correction for uptake time the correlation of SUV measures and TLG between the 60- and 90-min data significantly improved without affecting test-retest performance. CONCLUSION: This study suggests that a 15% change of SUVmean/SUVpeak at 60 min after injection can be used to assess response in advanced NSCLC patients if up to 5 PERCIST target lesions are assessed. Lower thresholds could be used in averaged PERCIST target lesions (<10%).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.115.170225

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SUV of tumor lesions increases steadily over time after [18F]FDG injection.

    “The SUV of tumor lesions, therefore, increases steadily over time after [18F]FDG injection [70,71].”

    From Influences on PET Quantification and Interpretation (2022) · cites this paper as [70]

    The Uptake Time Correction section (page not available) reports that tumor uptake was significantly higher at 90 minutes than at 60 minutes after injection. Those two measurements support an increase over that interval, but do not establish that SUV increases steadily throughout the time after injection. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kramer, G. M., Frings, V., Hoetjes, N., Hoekstra, O. S., Smit, E. F., de Langen, A. J., & Boellaard, R.
Affiliations
  • Gemeente Amsterdam (NL)
  • The Netherlands Cancer Institute (NL)
Venue
Journal of Nuclear Medicine
Published
2016-04-21
Volume
57
Issue
9
Pages
1343-1349
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W2335867152
Cited by
65
References
26
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 13 · 2020: 10 · 2019: 4 · 2018: 9 · 2017: 9 · 2016: 3
FWCI
7.23
Type
journal article
Language
en
Open access
Locations
  • Journal of Nuclear Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
18F-FDG PET/CT, non-small cell lung cancer, test-retest repeatability, lesion selection, PERCIST, standardized uptake value, total lesion glycolysis, tumor-to-blood ratio, tumor-to-liver ratio, treatment response assessment
MeSH terms
Positron Emission Tomography Computed Tomography, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Image Interpretation, Computer-Assisted, Lung Neoplasms, Male, Metabolic Clearance Rate, Middle Aged, Sensitivity and Specificity, Tissue Distribution, Reproducibility of Results, Radiopharmaceuticals, Fluorodeoxyglucose F18, Whole Body Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review